<DOC>
	<DOC>NCT00293813</DOC>
	<brief_summary>This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.</brief_summary>
	<brief_title>A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Key Postmenopausal, ambulatory women between 50 and 70 years old who are generally in good health. Must have low bone mineral density and meet specific eligibility criteria. Key Subjects must not currently be receiving any medication that affects bone metabolism or have an underlying condition that affects their ability to take alendronate or receive denosumab.</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Post Menopausal</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>MicroCT</keyword>
	<keyword>Amgen</keyword>
	<keyword>denosumab</keyword>
	<keyword>Extreme CT</keyword>
	<keyword>XCT</keyword>
	<keyword>Fosamax</keyword>
	<keyword>Alendronate</keyword>
</DOC>